Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

KaiNETIC-1

Fujian Shengdi Pharmaceutical Co · Phase 3 · Active, not recruiting · Enrollment 2530

NCT07284875

ArmPopulationDoseWeeksEstimandWeight change
Ribupatide: Dose 1Obesity or overweightn/rn/rn/rn/r
Ribupatide: Dose 2Obesity or overweightn/rn/rn/rn/r
Ribupatide: Dose 3Obesity or overweightn/rn/rn/rn/r
Ribupatide: Dose 4Obesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r